Literature DB >> 28737574

Is There a Role for Enterohormones in the Gastroparesis of Critically Ill Patients?

Carlos A Santacruz1, Amanda Quintairos, Claudia Righy, Ilaria A Crippa, Lucio Couto, Virginie Imbault, Mongkolpun Wasineeart, Mathieu De Ryckere, Jean-Charles Preiser.   

Abstract

OBJECTIVES: Delayed gastric emptying occurs in critically ill patients and impairs the delivery, digestion, and absorption of enteral feeding. A pathophysiologic role of the enterohormones peptide YY and ghrelin is supported by preclinical data. To compare the circulating plasma levels of peptide YY and ghrelin in control subjects and in critically ill patients, during feeding and fasting, and to search for a correlation with gastric emptying.
DESIGN: A prospective observational trial. SETTINGS: Mixed ICU of an academic hospital.
SUBJECTS: Healthy volunteers and patients expected to stay in ICU for at least 3 days in whom enteral nutrition was indicated.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Plasma peptide YY and ghrelin (enzyme-linked immunosorbent assay) were measured once in 10 fasting volunteers (controls) and daily from admission until day 5 of the ICU stay in 30 critically ill patients (median [interquartile range] age 63 [57-67] yr, median [interquartile range] Acute Physiology and Chronic Health Evaluation II score 21 [14-24]). Eight patients could not be fed (fasting group). In fed patients, 13 never had a gastric residual volume higher than 250 mL (low gastric residual volume group), in contrast to the high gastric residual volume group (n = 9). The plasma levels of peptide YY did not differ between patients (6.4 [0-18.1] pg/mL) and controls (4.8 [0.3-17.7] pg/mL). Ghrelin levels were lower in patients than in control (213 [54.4-522.7] vs 1,435 [1,321.9-1,869.3] pg/mL; p < 0.05). Plasma peptide YY or ghrelin did not differ between fasting and fed patients or between the high and low gastric residual volume groups.
CONCLUSIONS: In critically ill patients, plasma concentration of ghrelin significantly differs from that of controls, irrespective of the feeding status. No correlation was found between the temporal profile of ghrelin or peptide YY plasma concentration with bedside functional assessment of gastric emptying.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28737574     DOI: 10.1097/CCM.0000000000002625

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  4 in total

1.  When and how to manage enteral feeding intolerance?

Authors:  Yaseen M Arabi; Annika Reintam Blaser; Jean-Charles Preiser
Journal:  Intensive Care Med       Date:  2019-05-24       Impact factor: 17.440

2.  Leptin, Ghrelin, and Leptin/Ghrelin Ratio in Critically Ill Patients.

Authors:  Yaseen M Arabi; Dunia Jawdat; Hasan M Al-Dorzi; Hani Tamim; Waleed Tamimi; Abderrezak Bouchama; Musharaf Sadat; Lara Afesh; Mashan L Abdullah; Walid Mashaqbeh; Maram Sakhija; Abdulaziz Al-Dawood
Journal:  Nutrients       Date:  2019-12-21       Impact factor: 5.717

3.  Comparison of the effects of different calorie amounts of enteral nutrition in hypercatabolism associated with ghrelin-POMC in endotoxemic rats.

Authors:  Jianfeng Duan; Minhua Cheng; Yali Xu; Shaoqiu Tang; Xiaoyao Li; Yan Chen; Huimin Lu; Tao Gao; Wenkui Yu
Journal:  Nutr Metab (Lond)       Date:  2022-04-15       Impact factor: 4.654

4.  Gastrointestinal dysfunction in the critically ill: a systematic scoping review and research agenda proposed by the Section of Metabolism, Endocrinology and Nutrition of the European Society of Intensive Care Medicine.

Authors:  Annika Reintam Blaser; Jean-Charles Preiser; Sonja Fruhwald; Alexander Wilmer; Jan Wernerman; Carina Benstoem; Michael P Casaer; Joel Starkopf; Arthur van Zanten; Olav Rooyackers; Stephan M Jakob; Cecilia I Loudet; Danielle E Bear; Gunnar Elke; Matthias Kott; Ingmar Lautenschläger; Jörn Schäper; Jan Gunst; Christian Stoppe; Leda Nobile; Valentin Fuhrmann; Mette M Berger; Heleen M Oudemans-van Straaten; Yaseen M Arabi; Adam M Deane
Journal:  Crit Care       Date:  2020-05-15       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.